Compare Organon Pharma Indonesia Tbk. (SCPI) vs Summarecon Agung Tbk. (SMRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Summarecon Agung Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Summarecon Agung Tbk. trades at Rp332 (market cap 5.48T, 21M 24h volume). The key difference: Summarecon Agung Tbk. is far larger — about 52.5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | SMRA | |
|---|---|---|
Market Cap | 104.4B | 5.48T |
Volume | — | 21M |
Lot | — | 209.99K |
Turnover | — | 6.97B |
Average Price | — | 332.14 |
Value | — | 6.97B |
Indicative Equilibrium Price | — | 332 |
Indicative Equilibrium Volume | — | 19.86K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Summarecon Agung Tbk.
PT Summarecon Agung Tbk (the Company) was established within the framework of the Domestic Capital Investment Law based on notarial deed No. 308 dated November 26, 1975 of Ridwan Suselo, S.H. PT. Summarecon Agung Tbk is one of the nation`s leading township developers. Entering its twenty-forth year, the original 10-hectare landbank it started with has turned into a vibrant, 500 hectare township in North Jakarta where commercial vivacity peacefully coexists with its houses numbering in the tens of thousands.
Read more on SMRA →
